Using PRP injections to restore ovarian function in menopausal women
Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Menopausal Women
This study is testing whether PRP injections can help restore ovarian function in menopausal women and improve their hormone levels.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 45 Years to 55 Years |
| Sex | Female |
| Sponsor | Genesis Athens Clinic Academic / other |
| Locations | 1 site (Athens) |
| Trial ID | NCT03916978 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of autologous platelet-rich plasma (PRP) intra ovarian infusion in reactivating ovarian functionality and promoting folliculogenesis in menopausal women. The study is a triple-blind randomized controlled trial that aims to evaluate how PRP, enriched with growth factors, can stimulate tissue proliferation and improve hormonal profiles. Participants will receive either PRP or a placebo infusion, and their ovarian function will be monitored over time to assess the treatment's impact. The trial seeks to provide insights into the potential of PRP for ovarian rejuvenation, a concept that has not been fully explored in the context of menopause.
Who should consider this trial
Good fit: Ideal candidates are women aged 45-55 who have experienced amenorrhea for at least 12 months.
Not a fit: Patients with reproductive system disorders, previous ovarian insufficiency, or significant hormonal imbalances may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could restore ovarian function and improve fertility options for menopausal women.
How similar studies have performed: While PRP has shown promise in other medical fields, its application for ovarian rejuvenation is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 45-55 years old * Amenorrhea for at least 12 months * Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment. * Willing to comply with study requirements Exclusion Criteria: * Any pathological disorder related to reproductive system anatomy * Previous POI diagnosis * Abnormal karyotype * Endometriosis * Adenomyosis * Fibroids and adhesions * Infections in reproductive system * Current or previous diagnosis of reproductive system cancer * History of familiar cancer in reproductive system * Severe male factor infertility * Prior referral for PGT * Ovarian inaccessibility * Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * BMI\>30 kg/m2 or BMI\<18.5 kg/m2 * Systematic autoimmune disorders
Where this trial is running
Athens
- Genesis AC — Athens, Greece (Recruiting)
Study contacts
- Principal investigator: Agni Pantou, MD — Centre of Human Reproduction, Genesis Athens Clinic
- Study coordinator: Mara Simopoulou, PhD
- Email: marasimopoulou@hotmail.com
- Phone: +306979234100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.